Osteoboost Health Inc. has closed an $8 million financing round to scale manufacturing, expand clinical research and broaden commercialization of its FDA-cleared medical device designed to treat low bone density, the company announced.
The round was led by Ambit Health Ventures, with participation from Emmeline Ventures, Disrupt Health Impact Fund and existing investors Esplanade Ventures and Portfolia.
Related: Sonire Therapeutics raises $18M for tumour ablation platform advancement
The company’s device, a Class II prescription product, is positioned as a non-drug treatment for postmenopausal women with osteopenia, a condition that often precedes osteoporosis. Osteoporosis affects nearly 10 million Americans, with an additional 44 million estimated to have low bone density, according to the company.
“The cost of osteoporosis to society is enormous, but this is not a condition that begins at diagnosis,” said Laura Yecies, the company’s chief executive officer. “It develops silently over many years. That’s why earlier intervention and prevention are so critical.”
The wearable device is worn around the hips and delivers low-magnitude vibration therapy to the lumbar spine and hips, areas particularly vulnerable to fracture. The treatment approach is based on research originally funded by NASA.
In a double-blind clinical trial conducted at the University of Nebraska Medical Center, patients using the device at least three times per week for 30-minute sessions over 12 months saw bone density loss reduced by 85% in the spine and 55% in the hips, the company said.
The device addresses a gap in care, according to clinicians, particularly for patients with osteopenia who may not yet qualify for drug therapy.
“For years, when a patient with osteopenia asked what they could do beyond calcium, vitamin D and exercise, we didn’t have much to offer,” said David B. Karpf, an endocrinologist at Stanford University School of Medicine. “The availability of the FDA-approved Osteoboost device provides a clinically supported, non-drug option that allows us to intervene earlier.”
The company said its device was designated a Breakthrough Device by the U.S. Food and Drug Administration in 2024 and later cleared through the De Novo pathway. It began shipping in May and has since been prescribed by more than 2,500 physicians, including clinicians at more than 30 academic medical centers. The product was also named to TIME’s 2025 list of Best Inventions.
Osteoboost also offers a digital training platform, Wellen, designed by physical therapists for patients with osteoporosis. In a study of 680 participants, users improved lower-body strength by 22.8% after completing an 18-session program, with nearly 80% of those at elevated fall risk improving to average or above-average levels.
Investors say the company is targeting a large and under-addressed segment of women’s health.
“Half of women over 50 will experience a fracture due to bone loss, yet osteoporosis remains dramatically underdiagnosed and undertreated,” said Azin Radsan van Alebeek, co-founder and general partner at Emmeline Ventures.
A January 2026 World Economic Forum report found that women’s health receives about 6% of private health care capital, with most funding concentrated in reproductive health, maternal care and oncology. Meanwhile, the World Health Organization projects that by 2030, one in six people worldwide will be age 60 or older, increasing demand for solutions that support mobility and independence.
Early investor Esther Dyson, who also uses the device, said the technology offers an alternative to pharmaceutical approaches for patients seeking preventive care.
“I’m excited to see an alternative to the standard pharmaceutical approach,” Dyson said.
